Davies, Daniel
Kamdar, Shraddha
Woolf, Richard
Zlatareva, Iva
Iannitto, Maria Luisa
Morton, Cienne
Haque, Yasmin
Martin, Hannah
Biswas, Dhruva
Ndagire, Susan
Munonyara, Martina
Gillett, Cheryl
O’Neill, Olga
Nussbaumer, Oliver
Hayday, Adrian http://orcid.org/0000-0002-9495-5793
Funding for this research was provided by:
Wellcome Trust (220589/Z/20/Z)
Takeda Pharmaceutical Company
RCUK | Medical Research Council (MR/K002627/1)
Francis Crick Institute
Article History
Received: 10 May 2023
Accepted: 15 November 2023
First Online: 3 January 2024
Competing interests
: D.D., S.K. and M.L.I. were previously employed on a sponsored research agreement with Gamma Delta Therapeutics. D.D. and S.K. are currently employed on a sponsored research agreement with Takeda Pharmaceuticals (starting in February 2023). I.Z. was previously employed on a sponsored research agreement with Takeda Pharmaceuticals (February–July 2023). D.B. reports personal fees from NanoString and AstraZeneca and has a patent (PCT/GB2020/050221) issued on methods for cancer prognostication. A.H. receives laboratory research funding from Takeda Pharmaceuticals (starting in February 2023) and consults for eGenesis and Prokarium. Y.W. consults for PersonGen Biotherapeutics and E15 VC. The remaining authors declare no competing interests.